| High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial BH Grønberg, KT Killingberg, Ø Fløtten, OT Brustugun, K Hornslien, ... The Lancet Oncology 22 (3), 321-331, 2021 | 100 | 2021 |
| Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors M Skribek, K Rounis, S Afshar, O Grundberg, S Friesland, G Tsakonas, ... European Journal of Cancer 145, 245-254, 2021 | 73 | 2021 |
| Management of brain metastasized non-small cell lung cancer (NSCLC)–From local treatment to new systemic therapies G Tsakonas, L De Petris, S Ekman Cancer Treatment Reviews 54, 122-131, 2017 | 58 | 2017 |
| Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations? R Califano, F Gomes, CJ Ackermann, S Rafee, G Tsakonas, S Ekman European Journal of Cancer 125, 1-11, 2020 | 34 | 2020 |
| Cancer incidence and mortality patterns in women with anorexia nervosa G Karamanis, A Skalkidou, G Tsakonas, L Brandt, A Ekbom, L Ekselius, ... International journal of cancer 134 (7), 1751-1757, 2014 | 34 | 2014 |
| c-MET as a biomarker in patients with surgically resected non-small cell lung cancer G Tsakonas, J Botling, P Micke, C Rivard, L LaFleur, J Mattsson, T Boyle, ... Lung Cancer 133, 69-74, 2019 | 27 | 2019 |
| Oncogene-addicted non-small cell lung cancer and immunotherapy G Tsakonas, S Ekman Journal of thoracic disease 10 (Suppl 13), S1547, 2018 | 27 | 2018 |
| PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas L Sooman, S Ekman, G Tsakonas, A Jaiswal, S Navani, PH Edqvist, ... Tumor Biology 35, 4479-4488, 2014 | 25 | 2014 |
| Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden S Tendler, V Grozman, R Lewensohn, G Tsakonas, K Viktorsson, ... Lung Cancer 120, 75-81, 2018 | 22 | 2018 |
| An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non–small-cell lung cancer G Tsakonas, R Lewensohn, J Botling, C Ortiz-Villalon, P Micke, ... European Journal of Cancer 132, 24-34, 2020 | 19 | 2020 |
| Outcome of patients with NSCLC and brain metastases treated with immune checkpoint inhibitors in a ‘real-life’setting M Skribek, K Rounis, D Makrakis, S Agelaki, D Mavroudis, L De Petris, ... Cancers 12 (12), 3707, 2020 | 17 | 2020 |
| Randomized phase ii study with cetuximab in combination with 5-FU and cisplatin or carboplatin vs. cetuximab in combination with paclitaxel and carboplatin for treatment of … G Tsakonas, L Specht, CA Kristensen, MHC Moreno, H Haugen Cange, ... Cancers 12 (11), 3110, 2020 | 17 | 2020 |
| Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift? K Chatzidionysiou, M Liapi, G Tsakonas, I Gunnarsson, A Catrina Clinical rheumatology 40, 1687-1695, 2021 | 16 | 2021 |
| Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of … S Friesland, G Tsakonas, C Kristensen, M Herlestam Calero Moren, ... Journal of Clinical Oncology 36 (15_suppl), 6032-6032, 2018 | 15 | 2018 |
| Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival L Sooman, J Lennartsson, J Gullbo, M Bergqvist, G Tsakonas, ... Medical Oncology 30, 1-6, 2013 | 15 | 2013 |
| Complications following novel therapies for non‐small cell lung cancer M Skribek, K Rounis, G Tsakonas, S Ekman Journal of Internal Medicine 291 (6), 732-754, 2022 | 14 | 2022 |
| Correlation of clinical parameters with intracranial outcome in non-small cell lung cancer patients with brain metastases treated with Pd-1/Pd-L1 inhibitors as monotherapy K Rounis, M Skribek, D Makrakis, L De Petris, S Agelaki, S Ekman, ... Cancers 13 (7), 1562, 2021 | 12 | 2021 |
| Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer D Kaźmierczak, IJZ Eide, R Gencheva, Y Lai, R Lewensohn, G Tsakonas, ... Translational Lung Cancer Research 11 (5), 722, 2022 | 10 | 2022 |
| Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer G Tsakonas, F Hellman, M Gubanski, S Friesland, S Tendler, ... Acta Oncologica 57 (2), 231-238, 2018 | 9 | 2018 |
| Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer D Kazmierczak, IJZ Eide, R Gencheva, Y Lai, R Lewensohn, G Tsakonas, ... Translational Lung Cancer Research 11 (5), 2022 | 6 | 2022 |
